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Introduction: In recent years the Grading of Recommendations Assessment, Development and Evaluation (GRADE)
methodology has often been used by international or national health authorities, or scientific societies, for
developing evidence-based treatment recommendations. However, the GRADE approach has never been used by
practicing physicians who aim at harmonizing their prescribing behaviours paying due attention to the best
available evidence. This paper describes the experience of a working group of psychiatrists who adopted the
GRADE approach to develop clinical recommendations on the use of psychotropic drugs in specialist mental
healthcare.
Case description: The project was conducted in the Department of Mental Health of Verona, Italy, a city located in
the north of Italy. At the beginning of 2012, psychiatrists with a specific interest in the rational use of psychotropic
drugs were identified and appointed as members of a Guideline Development Group (GDG). The first task of the
GDG was the identification of controversial areas in the use of psychotropic drugs, the definition of scoping
questions, and the identification of outcomes of interest. The GDG was supported by a scientific secretariat, who
searched the evidence, identified one or more systematic reviews matching the scoping questions, and drafted
GRADE tables.
Discussion and evaluation: On the basis of efficacy, acceptability, tolerability and safety data, considering the risk
of bias and confidence in estimates, and taking also into consideration preferences, values and practical aspects in
favour and against the intervention under scrutiny, a draft recommendation with its strength was formulated and
agreed by GDG members. Recommendations were submitted for consideration to all specialists of the Department,
discussed in two plenary sessions open to the whole staff, and finally approved at the end of 2012.
Conclusion: The present project of guideline development raised several challenging and innovating aspects,
including a “bottom-up” approach, as it was motivated by reasons that found agreement among specialists, those
who developed the recommendations were those who were supposed to follow them, and values, preferences
and feasibility issues were considered paying due attention to local context variables.
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Clinical practice guidelines have progressively become a
tool for supporting an evidence-based approach in
health care. Guidelines are mostly seen as tools for mak-
ing health practice more consistent and efficient and for
narrowing the gap between what clinicians do and what
scientific evidence supports [1-3].
In recent years new methodological approaches for ag-
gregating, synthesising and grading the quality of evi-
dence have progressively been developed, in order to
support a transparent and methodologically sound pro-
duction of clinical practice guidelines. One of these tools
is the GRADE methodology (Grading of Recommenda-
tions Assessment, Development and Evaluation) [4-6].
This methodology has already been used to produce
guidelines for several fields of medicine, including men-
tal health care [7]. For example, WHO developed a
model intervention guide within the mental health Gap
Action Programme (mhGAP) [8], which provides recom-
mendations to facilitate care at first and second level fa-
cilities by the non-specialist health care providers in low
and middle income countries.
However, the GRADE approach has never been used
by practicing physicians who aim at harmonizing their
prescribing behaviours paying due attention to the best
available evidence. This paper describes the experience
of a working group of psychiatrists who adopted the
GRADE approach to develop clinical recommendations
on the use of psychotropic drugs in specialist mental
healthcare. Here we highlight how the GRADE approach
was adapted to our local needs, and we raise for consid-
eration some challenging features of the whole process.
Case description
Setting
This project was conducted in the area of Verona, a city lo-
cated in the north of Italy (450,000 inhabitants). In this area
the main agency providing psychiatric care for the adult
population is the Department of Mental Health (DMH) [9].
The DMH is a unitary service, in which great emphasis is
given to communication between all staff members and to
integration between the various clinical activities. It com-
prises four inpatient units located in three general hospitals
and a network of outpatient and community facilities. The
inpatient units are open wards of 16 beds each and patients
can be admitted on a voluntary or compulsory basis. The
Section of Psychiatry of the University of Verona is actively
involved in the DMH activities in terms of clinical, teaching
and research activities. In the last ten years it developed
skills in the production of clinical trials, Cochrane reviews,
and evidence-based recommendations.
At the beginning of 2012 the DMH started a project
aimed at producing evidence-based recommendations for
the pharmacological treatment of complex clinicalsituations. Final goals were the implementation of a robust
and shared methodology for choosing and managing
pharmacological treatments, and the assessment of the
impact of recommendations on prescribing behaviours.
Working group composition
As initial step, psychiatrists with a specific interest in the
rational use of psychotropic drugs were identified and
appointed as members of a Guideline Development
Group (GDG) (Figure 1). The group included at least
one representatives from each of the four Mental Health
Services of the DMH. The GDG was supported by a sci-
entific secretariat, which included staff belonging to the
Unit of Clinical Psychopharmacology and Drug Epidemi-
ology of the University of Verona. The scientific secre-
tariat was asked to provide scientific coordination and
methodological support in the use of the GRADE ap-
proach. All GDG members and researchers of the scien-
tific secretariat completed a form reporting potential
financial and non-financial conflicts of interest.
Formulating questions and choosing outcomes
The first task of the GDG was the identification of contro-
versial areas in the use of psychotropic drugs. A clinician’s
perspective was chosen, and a list of controversial areas
was initially developed by the GDG and subsequently cir-
culated by email to all specialists of the Department, with
a request of providing feedback by highlighting the three
topics perceived as the most relevant and where guidance
was needed. Specialists were also allowed to make sugges-
tions by adding other topics that were not part of the ini-
tial list. On the basis of this consultation process, the
GDG selected the six most relevant topics, as follows:
1. Use of antipsychotics and benzodiazepines in
patients with agitation and/or aggressive behaviour
2. Use of antipsychotics, antidepressants,
benzodiazepines and mood stabilizers in patients
with borderline personality disorder
3. Use of medicines in patients with unipolar depression:
3a. treatment strategies in patients who do not
benefit from initial treatment
3b. treatment strategies in patients with resistantdepression
3c. duration of antidepressant treatment
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Figure 1 Diagram describing the process of recommendation development.
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6c. epilepsyEach topic was reformulated using the PICO framework
(Population, Intervention, Comparator, Outcome) into
one or more scoping questions, in order to facilitate the
process of searching and synthesizing the evidence. Fi-
nally, for each scoping question, the GDG discussed a
number of possible outcomes of interest and, on the basis
of relevance and clinical judgment, retained only those
that were considered important or critical. These out-
comes helped guide the subsequent phases of evidence re-
trieval, synthesis, and production of GRADE tables.
Searching, appraising, synthesizing and grading the
evidence
For each scoping question a member of the scientific
secretariat was appointed as focal point. Focal points
searched the evidence and identified one or more sys-
tematic reviews answering the scoping questions. We
did not include primary studies. Existing guidelinesbased on newly performed systematic reviews, such as
for example NICE guidelines, were included. Medline,
Embase, Psychinfo, CINAHL the Cochrane Library and
BMJ Clinical Evidence were routinely scanned to help
identify pertinent systematic reviews. For efficacy, only
systematic reviews of randomized trials were considered;
for tolerability and safety outcomes, systematic reviews
of observational studies were considered and, in selected
cases, individual observational studies were included.
Pragmatically, only recent reviews (three years) were se-
lected, and we gave priority to Cochrane reviews, assum-
ing a higher methodological standard and considering
that the standard of reporting the results of Cochrane
reviews is particularly suitable for producing GRADE ta-
bles. We matched for each outcome one systematic re-
view. If more than one systematic review was available,
sometimes providing conflicting results, this was
recorded using the footnote tool of GRADE tables. Focal
points critically appraised the evidence and drafted
GRADE tables using the software GRADEpro [10]. As
rating the quality of evidence for each included outcome
is highly subjective, in order to increase consistency and
reliability, the secretariat followed the instructions used
by WHO in the mhGAP project [11].
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ing a PICO table, a list of included systematic reviews,
GRADE tables and additional evidence that was not
graded, was drafted and analytically discussed by the
GDG. If the production of GRADE tables was not feas-
ible, a narrative approach was followed. Figure 2 pro-
vides an example of a GRADE table. It summarises the
evidence on the beneficial and harmful effects of using
haloperidol versus chlorpromazine in the treatment of
patients with acute agitation. An interesting aspect is
that the selected systematic review included different
data for different outcomes: for example, for efficacy a
total number of four studies were included, while for tol-
erability outcomes two or three studies contributed to
the evidence base. As a consequence, the column “qual-
ity” reports a judgment on the confidence in the overall
treatment estimate for each included outcome, as
according to GRADE quality does not refer to the in-
cluded systematic review, but rather to the confidence in
estimate for each included outcome.
Drafting the recommendations
The GDG critically appraised the evidence and sug-
gested revisions to the GRADE tables and to the whole
scoping documents. In addition, during GDG meetings,Quality assessment
No of 
studies
Design Risk of bias Inconsistency Indirectness Imprecision
Other 
considerat





serious2 no serious 
indirectness
serious3 none
































1 From Analysis 2.2 of Leucht 2007. Haloperidol dosages: 5mg (2 studies); 1-5mg (1 study); 5-
study).
2 Visual inspection of forest plot suggests some heterogeneity. I-squared=58%
3 Less than 200 patients included in the analysis, and CI ranges from substantial benefit with h
4 From Analysis 2.1 of Leucht 2007
5 Less than 200 patients included in the analysis, and CI ranges from substantial benefit with h
6 From Analysis 2.4 of Leucht 2007
7 From Analysis 2.6 of Leucht 2007
8 Less than 200 patients included in the analysis, and CI ranges from substantial benefit with c
Figure 2 Example of GRADE table summarizing the evidence on halo
acute agitation.considerations on values and preferences, practical as-
pects such as drug labels, approved indications and
safety warnings from regulatory agencies, feasibility is-
sues and local aspects, were raised and extensively
discussed. These considerations were incorporated into
the scoping documents as key aspects to consider in
addition to the background evidence when drafting a
recommendation. Again, we followed the instructions
used by WHO in the mhGAP project [11].
On the basis of efficacy, acceptability, tolerability and
safety data, and considering the risk of bias and confi-
dence in estimates, and taking also into consideration
preferences, values and practical aspects in favour and
against the intervention under scrutiny, a draft recom-
mendation with its strength was formulated, agreed by
GDG members, and reported at the end of each scoping
document. Following WHO methodology, recommenda-
tion strength was categorised into standard or strong.
Only when the GDG was very certain that benefits
outweighed risks and burdens a recommendation was
rated as strong.
Consensus and external review
Recommendations were submitted for consideration to
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30mg (1 study). Chlorpromazine dosages: 25mg (1 study); 50mg (2 studies); 25-300mg (1 
aloperidol to no benefit at all.
aloperidol to substantial benefit with chlorpromazine.





peridol versus chlorpromazine in the treatment of patients with
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back and suggestions obtained during these plenary ses-
sions, final recommendations were drafted by the GDG.
In addition, remarks and clinical considerations that
were considered useful to contextualise the recommen-
dations were added, although these were kept separated
from the formally approved recommendations. The re-
vised versions were circulated to all specialists for con-
sensus and final approval.
Dissemination
From each scoping document we extracted the PICO
table, a summary table of efficacy and tolerability data, a
summary table of additional considerations on values,
preferences and feasibility issues, and the recommenda-
tion with its remarks. These extracts were included in
an official document that was disseminated to all staff
both in print and electronic format. A professional de-
signer was involved in its production in order to maxi-
mise readability and usefulness.
Monitoring
The project started in January 2012, and in January 2013 we
were able to disseminate the recommendations (Figure 1).
In order to evaluate their impact on prescribing practices, a
list of indicators have been identified which descriptively
monitor the degree of coherence between what is reported
in the guidelines and what is actually done in clinical prac-
tice [12,13]. Using pharmacy databases, a local Psychiatric
Case Registry and other administrative sources of data, we
aim to compare prescribing practices before and after the
dissemination of guidelines.
Discussion and evaluation
Challenging aspects of the project
The present project of guideline development raised sev-
eral challenging aspects. A first issue is the GDG com-
position. According to standard GRADE procedure for
guideline development, a multi professional GDG with
physicians, nurses, pharmacists, methodologists, pa-
tients, representatives of patient and family associations,
hospital policy makers and other civil society representa-
tives is suggested in order to keep into consideration dif-
ferent perspectives and input [14,15]. By contrast, only
specialists working in the psychiatric facilities of the
local catchment area were selected. This is indubitably a
study limitation, which was carefully considered before
the GDG was appointed. However, we reasoned that the
present project was aimed at providing a concrete an-
swer to a specific need expressed by specialists, that is to
harmonize prescribing practices and give suggestions for
controversial clinical issues. Given such a clear mission,
strongly focused on specialists as target audience, it
came naturally to involve them all in the production ofrecommendations that would regulate their own behav-
iour. Researchers with a long experience in the field of
clinical trials, systematic reviews and guideline produc-
tion were nevertheless actively involved, but only as
members of the scientific secretariat.
A second challenge was that, according to GRADE
methodology, recommendations should be formulated
keeping into consideration not only the evidence base,
but also values, preferences and feasibility issues [16].
This aspect was given much value in the present project,
and long discussions concerned regulatory issues, warn-
ings issued by European or national or regional author-
ities and on the pros and cons of off-label prescribing.
Other discussions concerned value judgements, such as
the relevance of treating a specific clinical condition des-
pite the lack of background evidence, and feasibility con-
siderations, often related to local context variables, such
as for example medication availability in different psy-
chiatric settings [17]. A challenge of this approach was
the relative weight that these aspects should receive in
comparison with aspects related to the evidence base.
We note that in some circumstances there was a risk of
generating recommendations only loosely connected
with the background evidence. For example, while the
evidence base suggests that second-generation antipsy-
chotics may be beneficial in treatment-resistant depres-
sion with no reason to prefer one specific drug, the
GDG pointed out that in Italy only quetiapine has a for-
mal indication for use in this condition, and this was in-
corporated into the recommendation.
Other challenging aspects refer to the GRADE meth-
odology [11]. Indirectness was a major issue, as the
GDG realized that very often the patient population in-
cluded in clinical trials did not match with the target
population. Second, for several outcomes inserted in
GRADE tables no evidence was available, as trials usu-
ally employ outcome measures that can easily be mea-
sured but may not always be considered that relevant in
clinical practice. The extensive use of rating scales in
psychiatry is a paradigmatic example of this, as these
scales are seldom used in clinical practice and the clin-
ical interpretation of differences in mean scores is rather
obscure [18]. The GDG noted some exceptions, though.
For example, while many trials conducted in patients
with aggressive behaviour used as primary outcome a
rating scale score, some studies with a very pragmatic
design measured efficacy with a clinically sound indica-
tor, which was “being asleep 15 minutes and 4 hours
after the intervention” [19-21]. Third, for some scoping
questions evidence was not available in the form of sys-
tematic reviews or randomized trials, for example when
tolerability of psychotropic drugs in pregnant women or
in patients with medical comorbidity were addressed.
For these questions, data from observational studies and
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systematically reviewed, and GRADE tables could not be
produced. As we had no resources to conduct new sys-
tematic reviews of observational studies, a narrative ap-
proach was employed in these situations, but we
acknowledge it was far from being optimal as some stud-
ies might have been missed and quality of evidence was
not explicitly assessed.
Innovative aspects of the project
Clinical guidelines are usually developed by national or
local health authorities, international or national scien-
tific societies, non-governmental organizations [22]. This
approach has been described as “top-down”. Although
guideline development or endorsement by high reputa-
tion organizations, such as WHO for example, may the-
oretically increase their uptake in clinical practice [23],
there are disadvantages with this approach. First, those
who develop the guidelines are not those who are sup-
posed to follow them, who are only asked to work to
standards that were set by others; second, the produc-
tion of guidelines is usually motivated by reasons that
may not have found agreement among specialists, in-
cluding financial control and medico-legal aspects; third,
a “top-down approach” can hardly include values, prefer-
ences and feasibility issues that pay due attention to
local variables.
By contrast, in the present project a “bottom-up” ap-
proach was followed, starting from an explicit request for-
mulated by specialists who felt a need of implementing a
more rational and careful use of psychotropic drugs. The
whole project has been developed on these grounds, from
the composition of the GDG to the selection of topics,
from the involvement of specialists in the critical ap-
praisal of the evidence base to the inclusion of local
feasibility consideration. Specialists were involved
both in the technical process (systematic reviews of
relevant evidence) and in the social process (inter-
pretation of the results of the systematic review) of
guideline development. This approach provided doc-
tors with an opportunity of training their ability to
manage the evidence base, which is not straightfor-
ward for most doctors, and their attitude to explicitly
draft recommendations on prescribing behaviours.
The educational features of this project were formally
acknowledged by local institutions which provided
Continuing Medical Education (CME) credits to all
participants.
We still do not know if this “bottom-up” approach will
enhance guideline uptake in practice [24]. However, data
have consistently shown that guidelines are still under-
used by practitioners [25,26], and effective strategies for
dissemination and implementation are needed. This
holds true in health care in general [27] and in mentalhealthcare [28]. The work described here attempted to
engage specialists since the very initial steps of guideline
production, as an effort to maximise implementability.
Hopefully, the monitoring phase that is currently on-
going will clarify whether this process is likely to be an
effective implementation strategy.
Conclusions
The present project will be replicated in 2013, appointing
different psychiatrists of the DMH as members of the
GDG, and focusing on another set of controversial topics.
The GDG will also regularly check the need of updating
the existing guidelines. The scientific secretariat will be
unchanged and will assure continuity in terms of method-
ology and overall process. Although we acknowledge the
risk of guideline proliferation with an increasing issue of
quality and potential conflicts of interest [29], we note that
the experience described in the present paper suggests
that physicians may effectively organize themselves be-
coming proactively involved in the production of clinical
practice recommendations that adhere to internationally
accepted quality standards, in the absence of financial or
other kinds of conflicts of interest. We argue that the
product of these initiatives should be offered to policy
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